Navigation Links
European Science Foundation aims to strengthen 'regenerative medicine'
Date:6/19/2008

14 Member Organisations* of the European Science Foundation have launched a key initiative to keep Europe at the forefront of regenerative medicine; broadly defined as the development of stem cell therapies to restore lost, damaged, or ageing cells and tissues in the human body.

Stem cells are the body's 'master cells' that have not yet been programmed to perform a specific function. Most tissues have their own supply of stem cells, and it is becoming clear that if these cells can be given the appropriate biochemical instructions, they can 'differentiate' into new tissue. In this way, for example, stem cells could be seeded into damaged heart muscle to repair it.

Regenerative medicine has many advantages over more conventional ways of repairing or replacing damaged tissues or organs. Because the stem cells are taken from the person being treated, there are no problems with the body's immune system recognising the cells as 'foreign' and attempting to reject them, something that is still a problem with organ transplantation, for example.

To help ensure that Europe retains its competitive edge in the field, the ESF has launched REMEDIC, a research networking programme in regenerative medicine (13 May 2008). For the next five years a steering committee of 13 of Europe's leading specialists in regenerative medicine will organise a series of meetings and workshops to bring together experts to share ideas and develop new collaborations.

"I think this network will be very important to allow scientists in the field to share and disseminate information," says Professor Yrj Konttinen, of Biomedicum Helsinki in Finland, who chairs the steering committee. "The network is open, so we will be in contact with many different organisations with an interest in the field. We want to meet people, establish joint collaborations with existing programmes and we will also be seeking funding for new initiatives."

REMEDIC will concentrate on the potential of a particular type of cell in the body called mesenchymal stromal cells. These can be obtained from fat tissue and coaxed to differentiate into a range of cell types, including bone, cartilage and muscle. Once the cells are in the relevant tissue, their growth and proliferation can be protected by biomaterials, which are structures implanted into the body that can guide the growth of the new tissue.

REMEDIC's first workshop is planned for mid-August in Helsinki, and a call for short term and exchange visits will be launched in late 2008. REMEDIC is a Research Networking Programme managed by the European Medical Research Councils (EMRC) at the European Science Foundation.


'/>"/>

Contact: Dr. Fiona Kernan
fkernan@esf.org
33-388-762-180
European Science Foundation
Source:Eurekalert

Related biology news :

1. Last chance for media to register for ECCO 14 -- the European Cancer Conference
2. 2 French scientists win European award for communication
3. Three-way mating game of North American lizard found in distant European relative
4. European lead in reading past climates from ice cores
5. Hot spots the key to controlling European carp in Australia
6. IdentiPHI Opens Paris Office to Boost European Sales and Support
7. European Union forests expanding, absorbing carbon at surprisingly high rate: study
8. First European Lung Cancer Conference
9. ESFs European ice core project EPICA receives prestigious Descartes Prize
10. European membrane expertise to focus on new treatments for human diseases
11. European light research opens door for optical storage and computing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 8, 2016  Singulex, Inc., the leader in Next ... into a license and supply agreement with Thermo Fisher ... provides Singulex access to Thermo Scientific BRAHMS PCT (Procalcitonin), ... is used to diagnose systemic bacterial infection and sepsis ... to aid in assessing the risk of critically ill ...
(Date:12/6/2016)... WARSAW, Ind. , Dec. 6, 2016  Zimmer Biomet ... that it has priced an offering of €500.0 million principal ... €500.0 million principal amount of its 2.425% senior unsecured notes ... is expected to occur on December 13, 2016, subject to the ... on an annual basis. ...
(Date:12/2/2016)... Texas , Dec. 1, 2016   ... today announced BioLock , an electrocardiogram (ECG) ... health monitoring, a key IoT asset. The smart ... into a vehicle,s steering wheel and mobile devices ... simple touch. As vehicle technology advances, ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... 8, 2016  Renova™ Therapeutics, a biotechnology company ... and type 2 diabetes, announced that it has ... virus (AAV) vector developed in the laboratory of ... Stanford University. The company plans to use this ... product pipeline. "Early research has ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... SDK that provide essential device-to-computer interconnect using USB or PCI Express, announced the ... support. The FOMD-ACV-A4 is a small, thin, SODIMM-style module that fits a standard ...
(Date:12/8/2016)... 8, 2016  Anaconda BioMed S.L., a pre-clinical stage ... next generation neuro-thrombectomy system for the treatment of Acute ... Jovin, MD to join its Scientific Advisory Board (SAB). ... network of scientific and clinical experts to Anaconda BioMed ... ANCD BRAIN ® to its clinical phase. The ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... World Technology Awards. uBiome is one of just six company finalists in the ... In addition to uBiome, companies nominated as finalists in this year’s awards include ...
Breaking Biology Technology: